Clinical trials: Hematologic
Non-Immune Hydrops Fetalis
Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops (NIH) Fetalis by Massively Parallel Sequencing
A fetal hydrops, also called a fetal anasarca, is the buildup of fluid in the serosa and / or fetal subcutaneous tissue. The diagnosis is made by ultrasound, possibly from the first trimester of pregnancy.
- Trial name
- ANAMETAB-PRO (NCT04308603)
- Testing
- NON-IMMUNE HYDROPS FETALIS diagnosis
- Where
- 17 sites in France
- Volunteers
- 71 people
- Sponsor
- Hospices Civils de Lyon
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Personalized NK Cell Therapy in CBT
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in treating patients with myelodysplastic syndrome, leukemia, lymphoma or…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT02727803
- Testing
- Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Iron-deficiency Anemia
IHAT Absorption Kinetics
At MRC Human Nutrition Research, the investigators have developed an engineered analogue of the ferritin-core for safe and effective iron supplementation.
- Trial name
- NCT02498886
- Testing
- IHAT, Ferrous sulphate
- Where
- The Gambia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Medical Research Council
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
This phase II trial studies how well sorafenib tosylate and chemotherapy work in treating older patients with acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Acute Promyelocytic Leukemia With PML-RARA
- Trial name
- NCT01253070
- Testing
- Biopsy, Bone Marrow Aspiration, Cytarabine
- Where
- 43 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Platelet Storage Pool Deficiency
Effect of Storage Condition on CD47 Expression Level in Platelet Concentrate
Effect of storage condition on CD47 expression level in platelet concentrate
- Trial name
- NCT05529394
- Volunteers
- 1 people
- Sponsor
- Assiut University
Lymphoma, Quality of Life
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Studying the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care.
- Trial name
- NCT00098566
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Cardiovascular Diseases, Sickle Cell Disease
SCD Fit Homebase Program
The purpose of this project is to develop novel approaches to promote health and longevity while enhancing quality of life among persons with Sickle cell disease (SCD).
- Conditions
- Cardiovascular Diseases, Sickle Cell Disease, Exercise
- Trial name
- NCT05228756
- Testing
- Accelerometer
- Sponsor
- University of Alabama at Birmingham
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
A Phase 3 clinical trial to examine the efficacy of duvelisib monotherapy versus ofatumumab monotherapy in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
- Trial name
- NCT02004522
- Testing
- Duvelisib, Ofatumumab
- Where
- 92 sites in United States, Australia and 9 more
- Volunteers
- 319 people
- Sponsor
- SecuraBio
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
This phase II trial tests how well pirtobrutinib (LOXO-305) and venetoclax works in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that remains despite treatment (resistant) with…
- Trial name
- NCT06466122
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Kerry Rogers
Anemia, Sickle Cell
Specifying Interventions From the Sickle Cell Disease Implementation Consortium (SCDIC)
The goal of this study is to specify the interventions, implementation strategies and control conditions from the Sickle Cell Disease Implementation Consortium (SCDIC) using a mixed-methods approach to study site materials and…
- Trial name
- NCT03380351
- Testing
- SCDIC interventions
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Inflammatory Response, Perioperative Hypothermia
Effects of Intraoperative Warming Methods on Hematologic Inflammatory Indices in Laparoscopic Cholecystectomy
Perioperative hypothermia is a frequent and preventable complication that may cause adverse outcomes such as increased blood loss, impaired coagulation, and delayed recovery.
- Conditions
- Inflammatory Response, Perioperative Hypothermia, Laparoscopic Cholecystectomy, Surgical Stress Response
- Trial name
- WARM-CHOL (NCT07232251)
- Testing
- Standard Active Warming Blanket, Intravenous Warmer Group, External Warmer Group
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Ataturk University
Cachexia, Lymphoma
Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer
RATIONALE: Nutritional supplements may help prevent loss of appetite, weight loss, and fatigue in patients with advanced cancer.
- Conditions
- Cachexia, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00053053
- Testing
- Juven, Non-Juven Supplement
- Where
- 250 sites in United States, Canada
- Volunteers
- 472 people
- Sponsor
- Radiation Therapy Oncology Group
Hemophilia
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
The purpose of this study is to examine the safety, tolerability and the way the body handles various single and multiple doses of ARC19499 in patients with hemophilia.
- Trial name
- NCT01191372
- Testing
- ARC19499
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Baxalta now part of Shire
Hypoxia, Anemia
Diastolic Deceleration Area in Late-onset FGR
DDA is a new Doppler parameter aiming to assess fetal well-being in-utero. Late-onset FGR is a specific subgroup of fetuses where the clinical application of this Doppler modality could play an essential role in detecting…
- Trial name
- NCT05837195
- Testing
- DDA Doppler
- Where
- Bulgaria
- Volunteers
- 300 people
- Sponsor
- Orthogyn Medical Center, Bulgaria
Lymphoblastic Leukemia, Acute, Childhood
N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia
The goal of this clinical trial is to analyze the effect of N-Acetylcysteine administration towards blood oxidant level, transaminase enzyme, and bilirubin level in ALL children who undergo induction phase of chemotherapy.
- Trial name
- NCT05611086
- Testing
- N-Acetylcysteine
- Where
- Indonesia
- Volunteers
- 16 people
- Sponsor
- Teny Tjitra Sari
Acute Myelogenous Leukemia, Myelogenous Leukemia
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of…
- Conditions
- Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
- Trial name
- NCT02203773
- Testing
- Posaconazole, ABT-199, Decitabine
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 212 people
- Sponsor
- AbbVie
Multiple Myeloma, Lymphoma
A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone
Hematopoietic stem cells (HSC) are used to support the administration of high dose chemotherapy for a range of human cancers. For a safe HSC transplantation, a minimum of 5 million HSC per kilogram are required.
- Trial name
- NCT00234169
- Testing
- VTP195183
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Von Willebrand Diseases
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
The VIVID study is structured in a master protocol format comprised of multiple parts that evaluate intravenous (IV) and subcutaneous (SC) VGA039 in healthy volunteers and subjects with von Willebrand Disease (VWD) and other…
- Trial name
- NCT05776069
- Testing
- VGA039
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Vega Therapeutics, Inc
Multiple Myeloma
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free…
- Trial name
- Cassiopeia (NCT02541383)
- Testing
- Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Daratumumab
- Where
- 107 sites in Belgium, France and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Intergroupe Francophone du Myelome
Leukemia
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth…
- Trial name
- NCT00268229
- Testing
- cytarabine, daunorubicin hydrochloride, imatinib mesylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- The Cleveland Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.